drugset / Trial / NCT07182721
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, single-center, Phase II clinical study designed to assess the preliminary efficacy and safety of SKB264 Plus Inetetamab plus inetetamab for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer following progression on prior T-DXd therapy.
Timeline
- Start
- 2025-09-30
- Primary completion
- 2028-09-30
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inetetamab | Monoclonal antibody | 4 mg/kg | — |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 5 mg/kg | — |